Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2045-2322
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan ; volume:8 ; number:1 ; day:10 ; month:5 ; year:2018 ; pages:1-11 ; date:12.2018
Scientific reports ; 8, Heft 1 (10.5.2018), 1-11, 12.2018
- Creator
-
Chang, Yi-Sheng
- Contributor
-
Lee, Wan-Ju
Lim, Chen-Chee
Wang, Shih-Hao
Hsu, Sheng-Min
Chen, Yi-Chian
Cheng, Chia-Yi
Teng, Yu-Ti
Huang, Yi-Hsun
Lai, Chun-Chieh
Tseng, Sung-Huei
SpringerLink (Online service)
- DOI
-
10.1038/s41598-018-25864-0
- URN
-
urn:nbn:de:101:1-2018070800473040980005
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:28 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Chang, Yi-Sheng
- Lee, Wan-Ju
- Lim, Chen-Chee
- Wang, Shih-Hao
- Hsu, Sheng-Min
- Chen, Yi-Chian
- Cheng, Chia-Yi
- Teng, Yu-Ti
- Huang, Yi-Hsun
- Lai, Chun-Chieh
- Tseng, Sung-Huei
- SpringerLink (Online service)
Other Objects (12)
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited
Prognostic factors for long term visual acuity outcome after Ranibizumab Therapy in patients with neovascular age-related macular degeneration
Macular functional changes in patients with neovascular age-related macular degeneration receiving ranibizumab therapy (lucentis)
Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Correction: Cost-Effectiveness Analysis of Ranibizumab Biosimilar for Neovascular Age-Related Macular Degeneration in Japan
Peripapillary choroidal thickness after intravitreal ranibizumab injections in eyes with neovascular age-related macular degeneration
Efficacy and safety of intravitreal aflibercept in ranibizumab-refractory patients with neovascular age-related macular degeneration
Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration
Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials
Macular Hole Formation Following Intravitreal Aflibercept for Neovascular Age-Related Macular Degeneration
Near-infrared reflectance imaging of neovascular age-related macular degeneration
Mineralocorticoid Antagonists as Adjuncts in Neovascular Age-Related Macular Degeneration
The comparative effectiveness and cost-effectiveness of ranibizumab for neovascular macular degeneration revisited